Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYCCP's Cash to Debt is ranked higher than
91% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. CYCCP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CYCCP' s 10-Year Cash to Debt Range
Min: 1  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.76
CYCCP's Equity to Asset is ranked higher than
59% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYCCP: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
CYCCP' s 10-Year Equity to Asset Range
Min: -3.51  Med: 0.76 Max: 0.88
Current: 0.76
-3.51
0.88
Interest Coverage No Debt
CYCCP's Interest Coverage is ranked higher than
84% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCCP: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYCCP' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -11.76
M-Score: -2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1206.76
CYCCP's Operating margin (%) is ranked lower than
80% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. CYCCP: -1206.76 )
Ranked among companies with meaningful Operating margin (%) only.
CYCCP' s 10-Year Operating margin (%) Range
Min: -66250  Med: -10492.35 Max: -1293.94
Current: -1206.76
-66250
-1293.94
Net-margin (%) -1050.27
CYCCP's Net-margin (%) is ranked lower than
80% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. CYCCP: -1050.27 )
Ranked among companies with meaningful Net-margin (%) only.
CYCCP' s 10-Year Net-margin (%) Range
Min: -65040  Med: -10857.06 Max: -936.62
Current: -1050.27
-65040
-936.62
ROE (%) -75.94
CYCCP's ROE (%) is ranked lower than
73% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CYCCP: -75.94 )
Ranked among companies with meaningful ROE (%) only.
CYCCP' s 10-Year ROE (%) Range
Min: -147.62  Med: -83.67 Max: -42.99
Current: -75.94
-147.62
-42.99
ROA (%) -57.91
CYCCP's ROA (%) is ranked lower than
74% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. CYCCP: -57.91 )
Ranked among companies with meaningful ROA (%) only.
CYCCP' s 10-Year ROA (%) Range
Min: -106.85  Med: -70.42 Max: -34.56
Current: -57.91
-106.85
-34.56
ROC (Joel Greenblatt) (%) -6327.95
CYCCP's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. CYCCP: -6327.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYCCP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10207.43  Med: -1645.65 Max: -481.96
Current: -6327.95
-10207.43
-481.96
EBITDA Growth (3Y)(%) -21.80
CYCCP's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. CYCCP: -21.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYCCP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -50.4  Med: -29.20 Max: 14.1
Current: -21.8
-50.4
14.1
EPS Growth (3Y)(%) -25.20
CYCCP's EPS Growth (3Y)(%) is ranked lower than
73% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. CYCCP: -25.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYCCP' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.8  Med: -30.15 Max: 19.3
Current: -25.2
-50.8
19.3
» CYCCP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CYCCP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP7.208.336% Convertible Exchangeable Preferred Stock

Ratios

vs
industry
vs
history
P/B 0.94
CYCCP's P/B is ranked higher than
96% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. CYCCP: 0.94 )
Ranked among companies with meaningful P/B only.
CYCCP' s 10-Year P/B Range
Min: 0.22  Med: 2.14 Max: 12.95
Current: 0.94
0.22
12.95
P/S 9.25
CYCCP's P/S is ranked higher than
62% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. CYCCP: 9.25 )
Ranked among companies with meaningful P/S only.
CYCCP' s 10-Year P/S Range
Min: 6.13  Med: 85.17 Max: 1190
Current: 9.25
6.13
1190
EV-to-EBIT 0.18
CYCCP's EV-to-EBIT is ranked higher than
97% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. CYCCP: 0.18 )
Ranked among companies with meaningful EV-to-EBIT only.
CYCCP' s 10-Year EV-to-EBIT Range
Min: -3.9  Med: -1.30 Max: 0.6
Current: 0.18
-3.9
0.6
Current Ratio 4.30
CYCCP's Current Ratio is ranked lower than
51% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CYCCP: 4.30 )
Ranked among companies with meaningful Current Ratio only.
CYCCP' s 10-Year Current Ratio Range
Min: 0.96  Med: 3.96 Max: 12.96
Current: 4.3
0.96
12.96
Quick Ratio 4.30
CYCCP's Quick Ratio is ranked higher than
51% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CYCCP: 4.30 )
Ranked among companies with meaningful Quick Ratio only.
CYCCP' s 10-Year Quick Ratio Range
Min: 0.96  Med: 3.96 Max: 12.96
Current: 4.3
0.96
12.96
Days Sales Outstanding 888.82
CYCCP's Days Sales Outstanding is ranked lower than
99% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. CYCCP: 888.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYCCP' s 10-Year Days Sales Outstanding Range
Min: 728.32  Med: 1560.30 Max: 6980.27
Current: 888.82
728.32
6980.27

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 8.33
CYCCP's Dividend Yield is ranked lower than
480% of the 218 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. CYCCP: 8.33 )
Ranked among companies with meaningful Dividend Yield only.
CYCCP' s 10-Year Dividend Yield Range
Min: 0  Med: 0.00 Max: 0
Current: 8.33
Yield on cost (5-Year) 8.33
CYCCP's Yield on cost (5-Year) is ranked lower than
470% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. CYCCP: 8.33 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
CYCCP' s 10-Year Yield on cost (5-Year) Range
Min: 0  Med: 0.00 Max: 0
Current: 8.33
Share Buyback Rate -45.10
CYCCP's Share Buyback Rate is ranked lower than
85% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. CYCCP: -45.10 )
Ranked among companies with meaningful Share Buyback Rate only.
CYCCP' s 10-Year Share Buyback Rate Range
Min: 5.7  Med: -39.40 Max: -144.4
Current: -45.1

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) 555.60
CYCCP's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CYCCP: 555.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYCCP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 166.5  Med: 312.30 Max: 20069.4
Current: 555.6
166.5
20069.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UXI2.Germany,
Cyclacel Pharmaceuticals Inc was founded in August 13, 1996 and is incorporated in Delaware. The Company is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Its clinical development priorities are focused on sapacitabine only, its second drug candidate, seliciclib, is a novel, orally-available, CDK clinical development priorities are focused on sapacitabine as an orphan drug for the treatment of both Acute Myeloid Leukemia, or AML, and Myelodysplastic Syndromes, or MDS. The Company is currently evaluating sapacitabine in a Phase 3 study being conducted under a Special Protocol Assessment, or SPA, with the FDA for the front-line treatment of AML in the elderly. The Company is also exploring sapacitabine in Phase 2 studies for MDS, non-small cell lung cancer, or NSCLC, and chronic lymphocytic leukemia, or CLL and in a Phase 1 study in solid tumors in combination with seliciclib, another of its drug candidates. Sapacitabine has been evaluated in approximately 1,000 patients to date. In addition, in polo-like kinase, or PLK inhibitor program, the Company has discovered CYC140 and other small molecule inhibitors of PLK1, a kinase active during cell division, targeting the mitotic phase of the cell cycle. The Company retains all marketing rights for these compounds internationally.
» More Articles for CYCCP

Headlines

Articles On GuruFocus.com
Wilbur Ross Buys Two New Stakes in First Quarter Jun 15 2015 
Insider Cluster Buying Reported in Several Companies May 30 2013 
View on CYCC Sep 11 2010 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Cyclacel Pharmaceuticals Inc shares climb 166% in two days Jan 10 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine... Jul 02 2015
First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine... Jul 02 2015
Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of... Jun 29 2015
Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of... Jun 29 2015
Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference Jun 17 2015
Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference Jun 17 2015
10-Q for Cyclacel Pharmaceuticals, Inc. May 14 2015
Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results May 12 2015
Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results May 12 2015
Cyclacel Pharmaceuticals to Release First Quarter 2015 Financial Results May 05 2015
Cyclacel Pharmaceuticals to Release First Quarter 2015 Financial Results May 05 2015
10-K for Cyclacel Pharmaceuticals, Inc. Apr 25 2015
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and... Apr 20 2015
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and... Apr 20 2015
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results Mar 24 2015
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2014 Financial Results Mar 17 2015
Cyclacel Pharmaceuticals Announces Pricing of Public Offering of Common Stock Mar 04 2015
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock Mar 03 2015
Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference Jan 06 2015
Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3... Dec 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK